: Rating increased to Strong Buy at Truist Financial.
Several biotechnology companies have recently earned ratings from analysts as of April 28, 2026. These ratings are often driven by positive clinical trial progress, strategic acquisitions, or analyst upgrades following strong performance. Latest Analyst "Strong Buy" Upgrades
: Rating increased to Strong Buy at Truist Financial.
Analysts have also highlighted smaller or more specialized innovators with high upside potential: Biotechnology - Yahoo Finance
According to TipRanks and Yahoo Finance , the following large-cap biotech stocks currently hold a consensus rating: Gilead Sciences (GILD) Regeneron Pharmaceuticals (REGN) BioNTech (BNTX) Insmed Incorporated (INSM) IQVIA Holdings (IQV) Emerging Growth & Specialized Picks
: Maintaining a Strong Buy outlook due to potential 2026 milestones . Top Biotech Stocks by Analyst Consensus
